A sobering new analysis from Treatment Action Group shows that governments failed to meet previous commitments to fund TB research.

Ahead of the UN General Assembly High-Level Meeting on TB, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

Treatment Action Group releases an updated Information note providing details on the new 0.15% fair share funding targets for TB research.

Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.

A toolkit, developed by Treatment Action Group, is designed to facilitate community participation in the development and review of clinical trials protocols.

Treatment Action Group (TAG) organized a webinar on 13 April 2023 providing an overview of the TB vaccine pipeline, based on TAG’s recent Tuberculosis Vaccines Pipeline Report, including the different candidates at different stages of research, and ongoing and upcoming studies that advocates should closely follow.

TAG and IMPAACT4TB project partners release several materials to explain how the identification of nitrosamines in rifampicin and rifapentine may affect the safety and supply of TB medicines, and what this may mean for TB programs and patients.

From the 2022 Union World Conference on Lung Health to the 2023 Conference on Retroviruses and Opportunistic Infections, several phase III treatment trials reported results with potential implications for TB policy and future research. On 14 March 2023, Treatment Action Group hosted a webinar where Dr. Jennifer Furin gave an overview of key results and how they fit into the larger TB policy and research landscapes.

Treatment Action Group (TAG) will host a webinar on 13 April 2023 that will provide an overview of the TB vaccine pipeline, based on TAG’s recent Tuberculosis Vaccines Pipeline Report, including the different candidates at different stages of research, and ongoing and upcoming studies that advocates should closely follow.

Treatment Action Group and the 1/4/6x24 Campaign Coalition launch the 1/4/6x24 World TB Day Toolkit to support advocacy the week of World TB Day for access to shorter, safer regimens for TB prevention and treatment.